Workflow
This
page
is
part
of
the
Snapshot
#3
for
FHIR
Specification
(v4.3.0:
R4B
-
STU
).
The
current
version
which
supercedes
this
version
is
5.0.0
R5
,
released
to
support
Connectathon
32
.
For
a
full
list
of
available
versions,
see
the
Directory
of
published
versions
.
Page
versions:
R5
R4B
R4
R3
| Clinical Decision Support Work Group | Maturity Level : N/A | Standards Status : Informative | Compartments : Not linked to any defined compartments |
Raw XML ( canonical form + also see XML Format Specification )
Chemotherapy Regimen (id = "KDN5")
<?xml version="1.0" encoding="UTF-8"?> <PlanDefinition xmlns="http://hl7.org/fhir"> <id value="KDN5"/> <text> <status value="additional"/> <div xmlns="http://www.w3.org/1999/xhtml"><table style="width: 100%;"><tr><td><!-- link to NCCN image --> <div style="width: 200px; height: 100px; vertical-align: top;">National Comprehensive Cancer Network</div></td><td><h3> Chemotherapy Order Template</h3><h1> Kidney Cancer</h1><h2> Gemcitabine/CARBOplatin</h2></td><td style="text-align: right; vertical-align: top;">KDN5</td></tr></table><table style="width: 100%; border-top: 1px solid; border-bottom: 1px solid;"><tr><td style="width: 33%; border-right: 1px solid; vertical-align: top"><h4> INDICATION:</h4><p> Metastatic or Relapsed – Collecting Duct/Medullary Subtypes</p></td><td style="width: 34%; border-right: 1px solid; vertical-align: top"><h4> REFERENCES:</h4><ol>http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AN D+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5DOudard S, et al. . 2007;177(5):1698-702.<li> <a href="http://www.example.org/professionals/physician_gls/PDF/kidney.pdf">NCCN Guidelines® for Kidney Cancer. V.3.2015.</a> </li> <li> <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpag e%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D">Oudard S, et al. <em> J Urol</em> . 2007;177(5):1698-702.</a> <sup> <a href="http://www.example.org/OrderTemplates/PDF/appendix_E.pdf">a</a> </sup> </li></ol></td><td style="width: 33%; vertical-align: top"><h4> NCCN SUPPORTIVE CARE:</h4><ol><li><i> Emetic Risk:</i><table><tr><td> Day 1</td><td> Moderate</td></tr><tr><td> Day 8</td><td> Low</td></tr></table></li><li>Refer to<i> Fever Neutropenia Risk:</i> <br/> Refer to <a href="http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf">NCCN Guidelines for Myeloid Growth Factors. V.2.2014</a> </li></ol></td></tr></table><!-- same as the regimen section of the Composition resource only this version is without the style guide notes --> <h4> CHEMOTHERAPY REGIMEN</h4><p><i> 21-day cycle for 6 cycles</i></p><ul>Gemcitabine 1250 mg/m IV over 30 minutes on Days 1 and 8<li> Gemcitabine 1250 mg/m<sup> 2</sup> IV over 30 minutes on Days 1 and 8</li> <li> CARBOplatin AUC 5 IV over 30 minutes on Day 1</li></ul></div> </text> <!-- regimen entries represented using contained ActivityDefinition resources (with extensions) --> <contained> <ActivityDefinition> <id value="1111"/> <status value="draft"/> <productCodeableConcept> <coding> <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/> <code value="12574"/> <display value="gemcitabine"/> </coding> <text value="gemcitabine"/> </productCodeableConcept> <dosage> <text value="1250 mg/m² IV over 30 minutes"/> <timing> <repeat> <duration value="30"/> <durationUnit value="min"/> </repeat> </timing> <route> <text value="IV"/> </route> <doseAndRate> <type> <coding> <system value="http://terminology.hl7.org/CodeSystem/dose-rate-type"/> <code value="ordered"/> <display value="Ordered"/> </coding> </type> <doseQuantity> <value value="1250"/> <unit value="mg/m²"/> </doseQuantity> </doseAndRate> </dosage> </ActivityDefinition> </contained> <contained> <ActivityDefinition> <id value="2222"/> <status value="draft"/> <productCodeableConcept> <coding> <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/> <code value="40048"/> <display value="Carboplatin"/> </coding> <text value="CARBOplatin"/> </productCodeableConcept> <dosage> <text value="AUC 5 IV over 30 minutes"/> <timing> <repeat> <duration value="30"/> <durationUnit value="min"/> </repeat> </timing> <route> <text value="IV"/> </route> <doseAndRate> <type> <coding> <system value="http://terminology.hl7.org/CodeSystem/dose-rate-type"/> <code value="ordered"/> <display value="Ordered"/> </coding> </type> <doseQuantity> <!-- AUC as dose unit or as an extension? --> <extension url="http://example.org/fhir/AUC-dose"> <valueInteger value="5"/> </extension> <!-- <value value="5" /> <unit value="AUC" /> <system value="http://snomed.info/sct" /> <code value="413573002" /> --> </doseQuantity> </doseAndRate> </dosage> </ActivityDefinition> </contained> <identifier> <system value="http://example.org/ordertemplates"/> <value value="KDN5"/> </identifier> <version value="1"/> <title value="Gemcitabine/CARBOplatin"/> <type> <text value="Chemotherapy Order Template"/> </type> <status value="draft"/> <experimental value="true"/> <publisher value="National Comprehensive Cancer Network, Inc."/> <!-- Indications --> <useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"> <valueString value="A"/> </extension> <code> <system value="http://example.org/fhir/CodeSystem/indications"/> <code value="treamentSetting-or-diseaseStatus"/> </code> <valueCodeableConcept> <text value="Metastatic"/> </valueCodeableConcept> </useContext> <useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"> <valueString value="A"/> </extension> <code> <system value="http://example.org/fhir/CodeSystem/indications"/> <code value="disease-or-histology"/> </code> <valueCodeableConcept> <text value="Collecting Duct/Medullary Subtypes"/> </valueCodeableConcept> </useContext> <useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"> <valueString value="A"/> </extension> <code> <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/> <code value="focus"/> </code> <valueCodeableConcept> <text value="Kidney Cancer"/> </valueCodeableConcept> </useContext> <useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"> <valueString value="B"/> </extension> <code> <system value="http://example.org/fhir/CodeSystem/indications"/> <code value="treatmentSetting-or-diseaseStatus"/> </code> <valueCodeableConcept> <text value="Relapsed"/> </valueCodeableConcept> </useContext> <useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"> <valueString value="B"/> </extension> <code> <system value="http://example.org/fhir/CodeSystem/indications"/> <code value="disease-or-histology"/> </code> <valueCodeableConcept> <text value="Collecting Duct/Medullary Subtypes"/> </valueCodeableConcept> </useContext> <useContext><extension url="http://hl7.org/fhir/StructureDefinition/usagecontext-group"> <valueString value="B"/> </extension> <code> <system value="http://terminology.hl7.org/CodeSystem/usage-context-type"/> <code value="focus"/> </code> <valueCodeableConcept> <text value="Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"/> </valueCodeableConcept> </useContext> <copyright value="All rights reserved."/> <approvalDate value="2016-07-27"/> <lastReviewDate value="2016-07-27"/> <author> <name value="Lee Surprenant"/> </author> <!-- list of references for the order template --> <relatedArtifact> <type value="derived-from"/> <display value="NCCN Guidelines for Kidney Cancer. V.2.2016"/><document> <url value="http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"/> </document> </relatedArtifact> <relatedArtifact> <type value="citation"> <extension url="http://example.org/fhir/regimenReferenceType"> <valueCode value="a"/> </extension> </type> <citation value="Oudard S, et al. J Urol. 2007;177(5):1698-702"/><document> <url value="http://www.ncbi.nlm.nih.gov/pubmed/17437788"/> </document> </relatedArtifact> <action> <!-- list of regimen options. in this case only one --> <selectionBehavior value="exactly-one"/> <action> <!-- list of regimen parts. in this case only one --> <selectionBehavior value="all"/> <action> <!-- list of cycle definitions. in this case only one --> <groupingBehavior value="sentence-group"/> <selectionBehavior value="exactly-one"/> <action id="cycle-definition-1"> <textEquivalent value="21-day cycle for 6 cycles"/> <timingTiming> <repeat> <count value="6"/> <duration value="21"/> <durationUnit value="d"/> </repeat> </timingTiming> <!-- list of regimen entry references for this regimen part --> <!-- references would duplicated in each cycle definition option (see codesystem-action-grouping-behavior.html#sentence-group) --> <action id="action-1"> <extension url="http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle"> <extension url="day"> <valueInteger value="1"/> </extension> <extension url="day"> <valueInteger value="8"/> </extension> </extension> <textEquivalent value="Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8"/> <definitionCanonical value="#1111"/> </action> <action id="action-2"> <extension url="http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle"> <extension url="day"> <valueInteger value="1"/> </extension> </extension> <textEquivalent value="CARBOplatin AUC 5 IV over 30 minutes on Day 1"/> <relatedAction><targetId value="action-1"/> <relationship value="concurrent-with-start"/> </relatedAction> <definitionCanonical value="#2222"/></action> <!-- end of regimen entries --> </action> <!-- end of cycle definitions --> </action> <!-- end of regimen parts --> </action> <!-- end of regimen options --> </action> </ PlanDefinition >
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR
®©
HL7.org
2011+.
FHIR
Release
4B
(v4.3.0)
hl7.fhir.r4b.core#4.3.0
R5
Ballot
hl7.fhir.core#5.0.0-snapshot3
generated
on
Sat,
May
28,
Wed,
Dec
14,
2022
12:56+1000.
07:17+1100.
Links:
Search
|
Version
History
|
Table
of
Contents
|
Glossary
|
QA
Page
|
Compare
to
R4
R4B
|
Compare
to
R5
Draft
|
|
Propose
a
change